Compare Stocks: APLM, BCYC, ACIU, and LXEO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$2.25 -2.6%	$2.64	$2.03 ▼ $4.00	$228.99M	1.56	267,577 shs	469,025 shs
APLM Apollomics	$19.78 -0.6%	$23.56	$10.01 ▼ $28.29	$57.56M	1.54	4,416 shs	91,520 shs
BCYC Bicycle Therapeutics	$3.78 +3.6%	$3.86	$3.33 ▼ $9.08	$264.57M	1.68	423,336 shs	486,229 shs
LXEO Lexeo Therapeutics	$2.87 +6.3%	$3.96	$2.55 ▼ $10.99	$235.47M	1.63	1.06 million shs	2.68 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	-4.55%	-4.94%	-8.33%	-0.43%	-28.92%
APLM Apollomics	-8.88%	-8.57%	-10.96%	+9.13%	-13.48%
BCYC Bicycle Therapeutics	+2.82%	+3.11%	-0.82%	-7.36%	-53.68%
LXEO Lexeo Therapeutics	-3.57%	-2.17%	-18.43%	-38.50%	-70.75%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACIU AC Immune	$2.25 -2.6%	$2.64	$2.03 ▼ $4.00	$228.99M	1.56	267,577 shs	469,025 shs
APLM Apollomics	$19.78 -0.6%	$23.56	$10.01 ▼ $28.29	$57.56M	1.54	4,416 shs	91,520 shs
BCYC Bicycle Therapeutics	$3.78 +3.6%	$3.86	$3.33 ▼ $9.08	$264.57M	1.68	423,336 shs	486,229 shs
LXEO Lexeo Therapeutics	$2.87 +6.3%	$3.96	$2.55 ▼ $10.99	$235.47M	1.63	1.06 million shs	2.68 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACIU AC Immune	-4.55%	-4.94%	-8.33%	-0.43%	-28.92%
APLM Apollomics	-8.88%	-8.57%	-10.96%	+9.13%	-13.48%
BCYC Bicycle Therapeutics	+2.82%	+3.11%	-0.82%	-7.36%	-53.68%
LXEO Lexeo Therapeutics	-3.57%	-2.17%	-18.43%	-38.50%	-70.75%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACIU AC Immune	2.80	Moderate Buy	$7.50	233.33% Upside
APLM Apollomics	1.00	Sell	N/A	N/A
BCYC Bicycle Therapeutics	2.30	Hold	$13.86	266.59% Upside
LXEO Lexeo Therapeutics	3.00	Buy	$16.43	472.42% Upside

Current Analyst Ratings Breakdown

Latest APLM, BCYC, ACIU, and LXEO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/20/2026	ACIU AC Immune	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
10/14/2026	BCYC Bicycle Therapeutics	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell
10/2/2026	ACIU AC Immune	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
10/2/2026	BCYC Bicycle Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (E+)
9/29/2026	ACIU AC Immune	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Strong-Buy
9/24/2026	ACIU AC Immune	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy
9/23/2026	ACIU AC Immune	BTIG Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$8.00
9/23/2026	LXEO Lexeo Therapeutics	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$15.00
9/22/2026	LXEO Lexeo Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Strong-Buy
9/17/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/1/2026	APLM Apollomics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 10/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACIU AC Immune	$17.51M	13.08	N/A	N/A	$0.54 per share	4.17
APLM Apollomics	$8.50M	6.77	N/A	N/A	($2.89) per share	-6.84
BCYC Bicycle Therapeutics	$61.21M	4.32	N/A	N/A	$8.79 per share	0.43
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	$3.38 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACIU AC Immune	-$85.03M	-$0.54	N/A	13.24	N/A	-245.32%	-100.17%	-28.36%	11/3/2026 (Estimated)
APLM Apollomics	-$10.94M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BCYC Bicycle Therapeutics	-$218.96M	-$2.73	N/A	N/A	N/A	-311.11%	-33.22%	-27.79%	10/29/2026 (Estimated)
LXEO Lexeo Therapeutics	-$99.96M	-$1.15	N/A	N/A	N/A	N/A	-41.85%	-38.03%	12/14/2026 (Estimated)

Latest APLM, BCYC, ACIU, and LXEO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	ACIU AC Immune	-$0.22	N/A	N/A	N/A	$0.33 million	N/A
10/29/2026	Q3 2026	BCYC Bicycle Therapeutics	-$0.3990	N/A	N/A	N/A	$12.22 million	N/A
8/12/2026	Q2 2026	LXEO Lexeo Therapeutics	-$0.2852	-$0.30	-$0.0148	-$0.30	N/A	N/A
8/6/2026	Q2 2026	ACIU AC Immune	-$0.1044	$0.03	+$0.1344	$0.0250	$9.59 million	$18.67 million
7/30/2026	Q2 2026	BCYC Bicycle Therapeutics	-$0.5756	-$0.72	-$0.1444	-$0.72	$4.22 million	$0.63 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACIU AC Immune	N/A	N/A	N/A	N/A	N/A
APLM Apollomics	N/A	N/A	N/A	N/A	N/A
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACIU AC Immune	0.11	0.93	N/A
APLM Apollomics	N/A	N/A	N/A
BCYC Bicycle Therapeutics	N/A	12.08	12.08
LXEO Lexeo Therapeutics	N/A	13.89	13.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACIU AC Immune	51.36%
APLM Apollomics	19.13%
BCYC Bicycle Therapeutics	86.15%
LXEO Lexeo Therapeutics	60.67%

Insider Ownership

Company	Insider Ownership
ACIU AC Immune	4.60%
APLM Apollomics	N/A
BCYC Bicycle Therapeutics	22.00%
LXEO Lexeo Therapeutics	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACIU AC Immune	106	101.77 million	97.09 million	Optionable
APLM Apollomics	15	2.91 million	N/A	Not Optionable
BCYC Bicycle Therapeutics	288	69.99 million	54.60 million	Optionable
LXEO Lexeo Therapeutics	59	82.05 million	80.41 million	Optionable

APLM, BCYC, ACIU, and LXEO Headlines

Recent News About These Companies

Lexeo Therapeutics Maps Gene Therapy Milestones, Eyes Key 2027 Readout

October 25 at 10:01 AM | marketbeat.com

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stock Rated "Buy" by Wall Street Analysts

October 24 at 8:58 AM | marketbeat.com

Lexeo Therapeutics Eyes NSVT Data as Key Test for LX2020 Gene Therapy

October 24 at 3:01 AM | marketbeat.com

Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Down 3.7% - Time to Sell?

October 23, 2026 | americanbankingnews.com

Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Down 3.7% - Should You Sell?

October 23, 2026 | marketbeat.com

Lexeo Therapeutics, Inc. (LXEO) Discusses Clinical Assessment and Unmet Need in PKP2 Arrhythmogenic Cardiomyopathy Transcript

October 21, 2026 | seekingalpha.com

Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM

October 19, 2026 | markets.businessinsider.com

Lexeo Therapeutics to Participate in the Chardan Healthcare Conference

October 8, 2026 | globenewswire.com

Stifel Nicolaus Sticks to Its Buy Rating for Lexeo Therapeutics, Inc. (LXEO)

October 7, 2026 | theglobeandmail.com

Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)

October 1, 2026 | finance.yahoo.com

Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson's Disease and Movement Disorders 2026 (MDS)

October 1, 2026 | globenewswire.com

490,331 Shares of Lexeo Therapeutics, Inc. $LXEO Purchased by Bank of America Corp DE

October 1, 2026 | marketbeat.com

【LXEO】Lexeo Therapeutics

September 29, 2026 | note.comN

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from Brokerages

September 29, 2026 | marketbeat.com

Leerink Partners Keeps Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)

September 26, 2026 | theglobeandmail.com

Lexeo to acquire Mantle Therapeutics

September 24, 2026 | thepharmaletter.comT

Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia

September 23, 2026 | prnewswire.com

Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

September 23, 2026 | globenewswire.com

Lexeo Therapeutics, Inc. agreed to acquire Mantle Therapeutics Inc. for $21.3 million .

September 22, 2026 | marketscreener.comM

Lexeo Therapeutics to Acquire Mantle Therapeutics for Up to $21.3 Million; Enters Three Research Collaborations

September 22, 2026 | finance.yahoo.com

Lexeo Therapeutics Signs Series Of Strategic Transactions To Expand Presence In Friedreich Ataxia

September 22, 2026 | rttnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM, BCYC, ACIU, and LXEO Company Descriptions

AC Immune NASDAQ:ACIU

$2.25 -0.06 (-2.60%)

Closing price 04:00 PM Eastern

Extended Trading

$2.26 +0.00 (+0.22%)

As of 04:10 PM Eastern

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Apollomics NASDAQ:APLM

$19.78 -0.12 (-0.60%)

Closing price 03:58 PM Eastern

Extended Trading

$19.78 0.00 (-0.01%)

As of 04:10 PM Eastern

Apollomics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company's products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain. Its also developing uproleselan (APL-106) that is in Phase 3 clinical trial for the treatment of adult patients with relapsed or refractory AML, as well as Phase 2/3 study with uproleselan for the treatment of newly diagnosed older adults with AML; and APL-108, a second-generation E-selective inhibitor, which has completed Phase 1 clinical trials to treat other liquid and solid cancers. The company's pipeline consists of preclinical stage immuno-oncology product candidates, such as APL-501, APL-502, APL-801 and APL-810. Its solutions include tumor inhibitors, anti-cancer enhancers, and immune-oncology drugs. Apollomics, Inc. was formerly known as CBT Pharmaceuticals, Inc. and changed its name to Apollomics, Inc. in January 2019. The company was incorporated in 2015 and is based in Foster City, California.

Bicycle Therapeutics NASDAQ:BCYC

$3.78 +0.13 (+3.56%)

Closing price 04:00 PM Eastern

Extended Trading

$3.78 0.00 (-0.13%)

As of 04:10 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Lexeo Therapeutics NASDAQ:LXEO

$2.87 +0.17 (+6.30%)

Closing price 04:00 PM Eastern

Extended Trading

$2.92 +0.05 (+1.92%)

As of 05:18 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APLM, BCYC, ACIU, and LXEO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APLM, BCYC, ACIU, and LXEO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APLM, BCYC, ACIU, and LXEO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM, BCYC, ACIU, and LXEO Company Descriptions

AC Immune NASDAQ:ACIU

Apollomics NASDAQ:APLM

Bicycle Therapeutics NASDAQ:BCYC

Lexeo Therapeutics NASDAQ:LXEO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest APLM, BCYC, ACIU, and LXEO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest APLM, BCYC, ACIU, and LXEO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

APLM, BCYC, ACIU, and LXEO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLM, BCYC, ACIU, and LXEO Company Descriptions

AC Immune NASDAQ:ACIU

Apollomics NASDAQ:APLM

Bicycle Therapeutics NASDAQ:BCYC

Lexeo Therapeutics NASDAQ:LXEO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools